GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive Versant's backing in ...

Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

The largest price increases came from Leadiant Pharmaceuticals, a subsidiary of Italy-based Essetifin. Leadiant raised prices ...